Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD

1.74  -0.02 (-1.14%)

Fundamental Rating

1

Overall SABS gets a fundamental rating of 1 out of 10. We evaluated SABS against 560 industry peers in the Biotechnology industry. Both the profitability and financial health of SABS have multiple concerns. SABS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SABS had negative earnings in the past year.
In the past year SABS has reported a negative cash flow from operations.
SABS had negative earnings in 4 of the past 5 years.
In multiple years SABS reported negative operating cash flow during the last 5 years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -89.92%, SABS is doing worse than 72.50% of the companies in the same industry.
SABS's Return On Equity of -160.11% is on the low side compared to the rest of the industry. SABS is outperformed by 64.11% of its industry peers.
Industry RankSector Rank
ROA -89.92%
ROE -160.11%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SABS has been increased compared to 1 year ago.
Compared to 1 year ago, SABS has a worse debt to assets ratio.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

SABS has an Altman-Z score of -7.59. This is a bad value and indicates that SABS is not financially healthy and even has some risk of bankruptcy.
SABS has a worse Altman-Z score (-7.59) than 69.11% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that SABS is not too dependend on debt financing.
The Debt to Equity ratio of SABS (0.15) is worse than 68.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -7.59
ROIC/WACCN/A
WACC9.81%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.69 indicates that SABS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.69, SABS is doing worse than 80.89% of the companies in the same industry.
SABS has a Quick Ratio of 1.69. This is a normal value and indicates that SABS is financially healthy and should not expect problems in meeting its short term obligations.
SABS has a worse Quick ratio (1.69) than 79.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.69
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.07% over the past year.
SABS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -85.49%.
The Revenue for SABS have been decreasing by -72.10% on average. This is quite bad
EPS 1Y (TTM)42.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)-85.49%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

SABS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.52% yearly.
The Revenue is expected to grow by 109.95% on average over the next years. This is a very strong growth
EPS Next Y19.46%
EPS Next 2Y29.29%
EPS Next 3Y21.52%
EPS Next 5YN/A
Revenue Next Year-62.25%
Revenue Next 2Y-24.75%
Revenue Next 3Y-4.14%
Revenue Next 5Y109.95%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SABS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SABS's earnings are expected to grow with 21.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.29%
EPS Next 3Y21.52%

More info and screens

0

5. Dividend

5.1 Amount

SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (5/29/2025, 9:30:00 AM)

1.74

-0.02 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners28.14%
Inst Owner Change-15.82%
Ins Owners18.43%
Ins Owner Change-0.01%
Market Cap16.16M
Analysts84
Price Target9.18 (427.59%)
Short Float %1.28%
Short Ratio2.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.72%
Min EPS beat(2)-3.26%
Max EPS beat(2)46.7%
EPS beat(4)2
Avg EPS beat(4)18.54%
Min EPS beat(4)-3.26%
Max EPS beat(4)46.7%
EPS beat(8)5
Avg EPS beat(8)-37.53%
EPS beat(12)8
Avg EPS beat(12)-25.13%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-53.15%
Min Revenue beat(2)-100%
Max Revenue beat(2)-6.29%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.42%
PT rev (3m)-27.42%
EPS NQ rev (1m)-1.96%
EPS NQ rev (3m)10.61%
EPS NY rev (1m)1.12%
EPS NY rev (3m)1.34%
Revenue NQ rev (1m)-25%
Revenue NQ rev (3m)-62.5%
Revenue NY rev (1m)-25%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.79
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-3.7
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0.04
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.92%
ROE -160.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.69
Altman-Z -7.59
F-Score1
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y19.46%
EPS Next 2Y29.29%
EPS Next 3Y21.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-85.49%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-62.25%
Revenue Next 2Y-24.75%
Revenue Next 3Y-4.14%
Revenue Next 5Y109.95%
EBIT growth 1Y-0.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.83%
OCF growth 3YN/A
OCF growth 5YN/A